20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Scribe Therapeutics Inc. Common Stock (SCTX) operates in the BIOTECHNOLOGY industry and is headquartered in Alameda, United States with about 82 employees. Its market capitalization is roughly $292 million. In the fiscal year ended 2025-12-31, SCTX reported $51M in revenue and ($22M) in net income.
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States.
Interactive charts & full statements → Open the SCTX valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 |
|---|---|---|---|
| Total Revenue | $26M | $51M | $27M |
| Operating Income (EBIT) | ($39M) | ($26M) | ($43M) |
| Operating Margin % | -149.0% | -50.9% | -156.2% |
| Net Income | ($37M) | ($22M) | ($48M) |
| Net Margin % | -141.9% | -42.6% | -174.3% |
| EBITDA | ($32M) | ($18M) | ($32M) |
| Earnings Per Share (EPS) | — | $-1.24 | $-2.72 |
| Shares Outstanding (M) | 18M | 18M | 18M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Total Revenue | $2M | $2M | $5M | $17M |
| Operating Income (EBIT) | ($9M) | ($12M) | ($12M) | ($6M) |
| Operating Margin % | -489.8% | -556.5% | -237.4% | -32.5% |
| Net Income | ($6M) | ($17M) | ($10M) | ($3M) |
| Net Margin % | -337.7% | -776.9% | -202.2% | -20.0% |
| EBITDA | ($5M) | ($16M) | ($9M) | ($2M) |
| Earnings Per Share (EPS) | $-0.37 | $-0.99 | — | — |
| Shares Outstanding (M) | 18M | 18M | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 |
|---|---|---|---|
| Cash from Operations (CFO) | ($33M) | ($45M) | ($45M) |
| Capital Expenditures (CapEx) | $1M | $1M | $1M |
| Free Cash Flow (FCF) | ($34M) | ($46M) | ($47M) |
| FCF Margin % | -130.3% | -90.8% | -169.9% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Cash from Operations (CFO) | ($5M) | ($8M) | ($7M) | ($14M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($5M) | ($8M) | ($7M) | ($14M) |
| FCF Margin % | -278.8% | -339.1% | -144.3% | -82.4% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 |
|---|---|---|---|
| Total Assets | $58M | $78M | $128M |
| Cash & Cash Equivalents | $36M | $13M | $13M |
| Total Liabilities | $223M | $222M | $254M |
| Total Debt (Short + Long-Term) | $0M | $0M | $34M |
| Total Shareholders' Equity | ($165M) | ($143M) | ($126M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SCTX viewer.
About TickerBase · Data methodology & sources · Privacy · Terms